Home › Trials › NCT06405321
Clinical trial Recruiting at 1 site Observational Ages 18 to 75

Exploring treatment options for hepatocellular carcinoma

Official title: Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study in Guangxi, China (GUIDANCE)

Run by Guangxi Medical University · NCT06405321 · Data updated 2026-11-12

This study is testing different treatment combinations for liver cancer to see which ones work best and help patients live longer.

Quick facts

Study typeObservational
Ages18 Years to 75 Years
SexAll
Enrollment2000 (estimated)
SponsorGuangxi Medical University
Academic / other
Drugs / interventionschemotherapy, immunotherapy
Locations1 site (Nanning, China)
StatusRecruiting
StartedJanuary 1, 2019
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedJanuary 14, 2026
Trial IDNCT06405321 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients with histologically or clinically confirmed HCC who have received conversion or neoadjuvant therapy as their initial treatment.

Probably not a fit

Patients with concurrent malignancies, incomplete medical data, or follow-up times less than three months may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter retrospective study focuses on patients with hepatocellular carcinoma (HCC) who have received conversion or neoadjuvant therapy. The research aims to establish a comprehensive database from Guangxi province, China, to analyze the effectiveness and safety of various treatment combinations, including transarterial chemoembolization and targeted therapies. By evaluating patient outcomes, the study seeks to identify the most beneficial treatment strategies and follow-up options for HCC patients. The ultimate goal is to provide evidence supporting the use of conversion or neoadjuvant therapy in improving patient survival rates.

Why it matters

Potential benefit: If successful, this study could help identify optimal treatment strategies that improve survival outcomes for patients with hepatocellular carcinoma.

How similar studies have gone: While there have been studies on HCC treatments, the specific focus on conversion or neoadjuvant therapy in this context is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Histologically or clinically confirmed diagnosis of HCC.
* Patients who received conversion or neoadjuvant therapy as initial treatment, including hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or radiotherapy.
* Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1.
* With Child-Pugh 5\~7 scores.

Exclusion Criteria:

* Concurrent with other malignancies within 5 years.
* Incomplete medical data.
* Follow-up time less than 3 months.

Where it's running

  • Jian-Hong Zhong
    Nanning, China, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • InstaSure Non-Invasive Finger-Press Test for HCC

    This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

    Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

  • BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

    This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

    Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

  • Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

    This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

    Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

  • 68Ga-SorB PET/CT imaging for solid tumors

    This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

    Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

  • Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)

    This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.

    Recruiting AstraZeneca · Al Mansurah and 16 other locations · NCT07650773

  • GLP-1 RA plus standard treatment in first-line metastatic GI cancers

    This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.

    Recruiting Early Phase 1 University of Arizona · Tucson, Arizona · NCT07627191

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Hepatocellular Carcinoma 412Guangxi Medical University 7
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.